BOSTON SCIENTIFIC CORP (BSX.DE) Stock Price, Quote, News and Overview
FRA:BSX - Deutsche Boerse Ag - US1011371077 - Common Stock - Currency: EUR
BSX.DE Quote, Performance and Key Statistics
BOSTON SCIENTIFIC CORP
FRA:BSX (1/22/2025, 7:00:00 PM)
97.5
+0.5 (+0.52%)
The current stock price of BSX.DE is 97.5 EUR. In the past month the price increased by 13.37%. In the past year, price increased by 84.87%.
BSX.DE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| IUI1.DE | INTUITIVE SURGICAL INC | 91.65 | 209.90B | ||
| 1ISRG.MI | INTUITIVE SURGICAL INC | 89.78 | 205.62B | ||
| ABL.DE | ABBOTT LABORATORIES | 26.41 | 198.32B | ||
| 2M6.DE | MEDTRONIC PLC | 16.84 | 108.61B | ||
| 1MDT.MI | MEDTRONIC PLC | 16.67 | 107.51B | ||
| BOX.DE | BECTON DICKINSON AND CO | 18.21 | 66.56B | ||
| SHL.DE | SIEMENS HEALTHINEERS AG | 24.37 | 61.30B | ||
| EWL.DE | EDWARDS LIFESCIENCES CORP | 26.12 | 39.43B | ||
| DC4.DE | DEXCOM INC | 51.69 | 32.91B | ||
| PHIA.AS | KONINKLIJKE PHILIPS NV | 19.86 | 24.08B | ||
| PHI1.DE | KONINKLIJKE PHILIPS NV | 19.77 | 23.97B | ||
| 1PHIA.MI | KONINKLIJKE PHILIPS NV | 19.42 | 23.55B |
Related screens
About BSX.DE
Company Profile
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 48,000 full-time employees. Its MedSurg segment includes Endoscopy, Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with less invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. Its Interventional Cardiology Therapies business develops and manufactures technologies for diagnosing and treating coronary artery disease and aortic valve conditions. The company also owns the transcarotid artery revascularization (TCAR) platform.
Company Info
BOSTON SCIENTIFIC CORP
300 Boston Scientific Way
Marlborough MASSACHUSETTS US
Employees: 48000
Company Website: https://www.bostonscientific.com/en-US/Home.html
Investor Relations: https://investors.bostonscientific.com
Phone: 15086834000
BSX.DE FAQ
What is the price of BSX.DE?
The current price of BSX.DE is 97.5 EUR.
What is the symbol for BOSTON SCIENTIFIC CORP?
The exchange symbol of BOSTON SCIENTIFIC CORP is BSX and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is BSX.DE listed?
BSX.DE is listed on the Deutsche Boerse Ag exchange.
Is BSX.DE a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for BSX.DE, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of BSX.DE.
Does BSX.DE pay dividends?
BSX.DE does not pay a dividend.
When does BSX.DE report earnings?
BSX.DE will report earnings on 2025-02-05, after the market close.
What is the Price/Earnings (PE) ratio of BSX.DE?
The PE ratio for BSX.DE is 43.14. This is based on the reported non-GAAP earnings per share of 2.26 and the current share price of 97.5 EUR.
BSX.DE Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to BSX.DE. When comparing the yearly performance of all stocks, BSX.DE is one of the better performing stocks in the market, outperforming 98.3% of all stocks.
BSX.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to BSX.DE. BSX.DE has only an average score on both its financial health and profitability.
BSX.DE Financial Highlights
Over the last trailing twelve months BSX.DE reported a non-GAAP Earnings per Share(EPS) of 2.26. The EPS increased by 18.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 11.27% | ||
| ROA | 4.71% | ||
| ROE | 8.66% | ||
| Debt/Equity | 0.45 |
BSX.DE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to BSX.DE. The Buy consensus is the average rating of analysts ratings from 38 analysts.
For the next year, analysts expect an EPS growth of 21.26% and a revenue growth 17.61% for BSX.DE